# EU approves Abbott's $25B acquisition of St. Jude Medical with divestiture conditions

The European Commission approved Abbott Laboratories' $25 billion cash-and-stock acquisition of St. Jude Medical, conditional on Abbott divesting two devices used in cardiovascular treatments.

- Type: Acquisition
- Announced: 2016-11-23
- Where: United States
- Value: $25.0B
- Status: announced
- Products: cardiovascular treatment devices
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Abbott Laboratories](https://endata.com/companies/20171.md) (acquirer)
- [St. Jude Medical](https://endata.com/companies/20172.md) (target)

## Sources

- [law360.com](https://www.law360.com/articles/865891/eu-oks-abbott-s-25b-acquisition-of-st-jude-with-caveats), 2016-11-23: "The European Commission said Wednesday it had given the green light to Abbott Laboratories' $25 billion cash-and-stock acquisition of device maker St. Jude Medical."
- [law360.com](https://www.law360.com/articles/876700/abbott-to-wrap-up-25b-st-jude-buy-with-ftc-s-approval), 2017-01-03: "Abbott Laboratories is set to close its $25 billion cash-and-stock acquisition of St. Jude Medical Inc. on Wednesday"
- [cardiacrhythmnews.com](https://cardiacrhythmnews.com/abbott-completes-the-acquisition-of-st-jude-medical/), 2017-01-05: "Abbott has now completed the acquisition of St Jude Medical."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.